NC9  (Synonyms: Cbz-Lys(Acr)-PEG2-dansyl)

NC9 (Cbz-Lys(Acr)-PEG2-dansyl) is an irreversible transglutaminase (TG) inhibitor. NC9 inhibits osteoblast differentiation and mineralization. NC9 destabilizes microtubules. NC9 can be used for the research of osteoblast differentiation^[1].

NC9 (50 μM; 12 days) reduces TG-activity down to 51% and decreases TG-mediated labeling of the cell layers^[1].
NC9 (50 μM; 12 days) inhibits mineral depositions in osteoblast cultures and reduces Ca₂₊ accumulation in cell-matrix layer^[1].
NC9 (50 μM; 12 days) blocks extracellular collagen type I (COL I) secretion and deposition, reduces fibronectin (FN) matrix formation and increases FN levels in the cytoskeleton and matrix fraction^[1].
NC9 (50 μM; 12 days) destabilizes microtubules with the decreasing of plasma membrane 150-kDa Glu-tubulin level and increasing of 50-kDa tubulin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

697.84

C₃₅H₄₇N₅O₈S

1352090-52-8

O=C(OCC1=CC=CC=C1)N[C@@H](CCCCNC(C=C)=O)C(NCCOCCOCCNS(=O)(C2=C3C=CC=C(N(C)C)C3=CC=C2)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Al-Jallad HF, et al. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS One. 2011 Jan 20;6(1):e15893.  [Content Brief]